![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, October 24, 2018 7:03:04 PM
It is the first time - quite unexpectedly from what I gather - that the abscopal effect generated by intratumoral administration of encoded IL-12 genes noticeably lacked exhaustion markers in tumor infiltrating lymphocytes found in untreated tumors. Typically this only happens during acute situations. If the new p2a-linked plasmid construct coupled with modified electroporation parameters has something to do with the significant improvements in intratumoral IL-12 expression and armoring of effector cells, then this is definitely a big deal. Obviously, just like everything else in immunology, the observations would need to translate into humans. But if it does, it could potentially negate the need for systemic anti-pd-1 agents!
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM